Anti-Human TRAIL R2/TNFRSF10B Reference Antibody (Lexatumumab, RUO)

Description: Lexatumumab (BS10237) is a research-grade recombinant antibody targeting CD262. Produced in mammalian cells with native-like glycosylation.
Highlights:
• Research Grade — For PK/PD studies, assay development, and ADA research.
• Native Glycosylation — Mammalian expression ensures native-like patterns.
Host species: Human
Isotype: IgG1-lambda
Species reactivity: Human
Immunogen:
Form: Liquid
Storage instructions:
Storage buffer: 0.01M PBS, pH7.4.
Concentration: 1mg/ml
Purity: >95% as determined by SDS-PAGE.
Clonality: Monoclonal
Applications: Research Grade Biosimilar
Target: TRAILR2,TRAIL-R2,Deathreceptor5,CD262,DR5,Tumornecrosisfactorreceptorsuperfamilymember10B,ZTNFR9,TRAILreceptor2,TRICK2,TNFRSF10B,KILLER,TNF-relatedapoptosis-inducingligandreceptor2
Purification: Protein A/G purified from cell culture supernatant.
Endotoxin level: <1EU/mg, determined by LAL gel clotting assay
Expression system: Mammalian Cells
Stability and Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names: HGS-ETR2,CAS:845816-02-6
Background: Tumor necrosis factor receptor superfamily member 10B (CD262/TRAIL-R2) is a ~47 kDa protein. Receptor for the cytotoxic ligand TNFSF10/TRAIL. The adapter molecule FADD recruits caspase-8 to the activated receptor. The resulting death-inducing signaling complex (DISC) performs caspase-8 proteolytic activation which initiates the subsequent cascade of caspases (aspartate-specific cysteine proteases) mediating apoptosis. Promotes the activation of NF-kappa-B. Essential for ER stress-induced apoptosis.
References:
1. Hymowitz, SG. et al. (1999) Molecular cell 4, 563-71. PMID: 10549288
Note: For research use only. Not suitable for clinical or therapeutic use.